Cytomos® brings together expertise and experience spanning biology, engineering, product development and project management
Dr Keith Muir
CEO & Founder
Keith founded Cytomos® having developed our proprietary sensing technology as part of his Ph.D in microelectronics awarded by The University of Edinburgh.
He has 7 years' experience of leading the company as executive director, being responsible for securing finance, protecting our IP, building our team, engaging with lead users and guiding our product development.
Dr Jeannette Watson
Director of Operations
Jeannette is a pharmacologist by training and has worked in the pharmaceutical arena for over 25 years. She has substantial experience in large pharma, where she successfully led projects from target validation to early phase clinical development.
She has since worked as a management team member in investor-funded biotechs and been responsible for delivering clinical development plans.
Alister has spent more than 20 years creating spinout and start-up companies and selling technology-led projects to global OEMs.
He has been a founder and Managing Director of a listed IP commercialisation company, a founder and VP Sales of a listed networking technology start-up and Business Group Manager at an imaging semiconductor spin-out that LSE-listed 3 years after he joined.
Margaret joined the life science industry in 1995 in Business Development for Q-One Biotech (now BioReliance) and has over 23 years' commercial management experience in the life science CRO sector.
In 2007, she co-founded Vitrology Ltd and served as CEO from 2008 through to its acquisition by the Swiss multinational SGS in 2012.
Dr Gino Miele
Gino is currently R&D director for AIM-listed Genedrive Diagnostics Ltd, where he is responsible for ISO13485 compliant biomedical instrumentation and assay chemistry product development for decentralised point of care molecular diagnostics testing.
Gino brings experience spanning research to commercially focussed service provision ranging from universities, small biotech, through to hospitals and large pharma.